KAIST Researchers Reprogram Immune Cells Within Tumors for Breakthrough Cancer Therapy
Table of Contents
A novel approach transforms existing immune cells into potent cancer fighters, overcoming a major hurdle in solid tumor treatment.
Macrophages, immune cells naturally equipped to attack cancer, are frequently enough rendered ineffective within the unfriendly habitat of a tumor. Now, a research team at the Korea Advanced Institute of science and Technology (KAIST) has unveiled a groundbreaking method to revitalize these cells, directly converting them into powerful anticancer agents. The findings, published November 18 in ACS Nano, offer a promising new direction for cancer immunotherapy, notably for difficult-to-treat solid tumors like those found in gastric, lung, and liver cancers.
The Challenge of Solid Tumors
Solid tumors present a formidable challenge to traditional immune therapies. Their dense structure physically blocks immune cells from infiltrating the tumor and effectively functioning. This creates a biological barrier that substantially limits the success of many existing treatments. As one researcher explained, this barrier has long hampered efforts to harness the body’s own immune system to fight cancer.
CAR-Macrophages: A Next-Generation Immunotherapy
CAR-macrophages – macrophages engineered to recognize and destroy cancer cells – have emerged as a promising next-generation immunotherapy. unlike some immune cells, macrophages can directly engulf and destroy cancer cells, and also stimulate surrounding immune cells, amplifying the body’s overall anticancer response. However, current methods for creating CAR-macrophages are complex and impractical. They require extracting a patient’s immune cells, modifying them in a lab, and then reinfusing them – a process that is slow, expensive, and difficult to scale for widespread use.
Reprogramming Immunity In-Situ
The KAIST team,led by Professor Ji-Ho Park from the Department of bio and brain Engineering,circumvented these limitations by focusing on tumor-associated macrophages – immune cells that naturally accumulate around tumors. Their innovative approach involves reprogramming these cells directly inside the body,eliminating the need for external manipulation.
The team developed a system utilizing lipid nanoparticles – tiny engineered particles designed to be readily absorbed by macrophages. These nanoparticles are loaded with both mRNA,carrying instructions for cancer recognition,and an immune-activating compound.This combination effectively “directly converts the body’s own macrophages into anticancer cell therapies inside the body,” according to the researchers.
Dramatic Results in Animal Studies
in animal models, the treatment demonstrated remarkable efficacy. When injected into tumors, macrophages rapidly absorbed the nanoparticles and began producing proteins that identify cancer cells. This triggered a powerful immune response, resulting in “enhanced CAR-macrophages” with significantly improved cancer-killing ability.The treatment also stimulated surrounding immune cells,leading to a robust anticancer effect.
notably, the study showed significant reduction in tumor growth in animal models of melanoma, the most risky form of skin cancer. Furthermore, researchers observed evidence that the immune response extended beyond the treated tumor, suggesting the potential for broader, body-wide immune protection. .
A New Era for Cancer Treatment
“This study presents a new concept of immune cell therapy that generates anticancer immune cells directly inside the patient’s body,” stated Professor Ji-Ho Park. He emphasized the significance of simultaneously overcoming key limitations of existing CAR-macrophage therapies – namely, delivery efficiency and the immunosuppressive tumor environment.
The research, spearheaded by Jun-Hee han, Ph.D., was supported by the Mid-Career Researcher Program of the National Research Foundation of Korea. This innovative approach represents a significant step forward in the fight against cancer, offering a potentially more effective and accessible immunotherapy for patients facing challenging diagnoses.
